# Merck Engineer - Scenario Reference

## Scenario 1: Keytruda Clinical Data System Issue

**Context**: During a Phase III Keytruda trial, the EDC system experiences data synchronization issues between sites and central database.

**Immediate Actions**:
1. Assess impact on data integrity
2. Notify Clinical Data Management and QA
3. Implement manual data reconciliation process
4. Engage vendor support

**Root Cause Analysis**:
- Network connectivity issues at certain sites
- API rate limiting during peak hours
- Database connection pool exhaustion

**Resolution**:
- Implement redundant connectivity
- Optimize API batch sizes
- Scale database infrastructure
- Document in deviation log

**Prevention**:
- Enhanced monitoring
- Load testing for peak enrollment
- Disaster recovery drills

---

## Scenario 2: Manufacturing Batch Deviation

**Context**: Keytruda manufacturing batch shows out-of-specification result during in-process testing.

**Immediate Actions**:
1. Quarantine batch and related materials
2. Notify Manufacturing and QA
3. Preserve all samples and data
4. Initiate deviation investigation

**Investigation Steps**:
1. Review batch record
2. Check equipment calibration
3. Analyze raw materials
4. Interview operators
5. Review environmental data

**Root Cause Possibilities**:
- Equipment malfunction
- Operator error
- Raw material variation
- Environmental excursion

**CAPA Development**:
- Corrective: Batch disposition, equipment repair
- Preventive: Enhanced monitoring, SOP updates, retraining

---

## Scenario 3: Supply Chain Disruption

**Context**: Natural disaster impacts Keytruda API supplier facility.

**Immediate Response**:
1. Activate Business Continuity Plan
2. Assess inventory position globally
3. Contact secondary suppliers
4. Notify regulatory affairs

**Short-Term Actions**:
- Accelerate shipments from alternate suppliers
- Reallocate inventory across markets
- Implement allocation protocol
- Customer communication

**Long-Term Actions**:
- Qualify additional suppliers
- Increase safety stock
- Diversify supply geography
- Update risk assessments

---

## Scenario 4: Cybersecurity Incident

**Context**: Suspicious activity detected in validated manufacturing system network.

**Immediate Response**:
1. Isolate affected systems
2. Activate Incident Response Team
3. Preserve forensic evidence
4. Assess GxP impact

**Investigation**:
- Forensic analysis
- Scope determination
- Root cause analysis
- Regulatory assessment

**Recovery**:
- System restoration from validated backups
- Security patches
- Enhanced monitoring
- User notification

**Regulatory Reporting**:
- FDA notification (if required)
- EU competent authorities
- Customer notification (if product impact)

---

## Scenario 5: Animal Health Manufacturing Technology Transfer

**Context**: Transfer BRAVECTO manufacturing process to new De Soto facility.

**Pre-Transfer Activities**:
- Process documentation review
- Equipment gap assessment
- Analytical method transfer
- Personnel training

**Engineering Runs**:
- 3+ successful engineering batches
- Side-by-side comparison
- Process parameter verification
- In-process control establishment

**Process Performance Qualification**:
- PPQ protocol execution
- Statistical analysis
- CQA verification
- Regulatory submission

**Commercial Launch**:
- Regulatory approval
- Commercial batch release
- Market supply transition
- Post-approval monitoring
